Corbus Pharmaceuticals Holdings, Inc. (CRBP) 10-Year Financial Performance & Capital Metrics

CRBP • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Show more

Revenue $0
EBITDA -$48M -8.3%
Net Income -$40M +9.9%
EPS (Diluted) -3.68 +64.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -59.34% +82.6%
ROIC -56.77% +65.3%
Debt/Equity 0.02
Interest Coverage -26.03 -68.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-74.45%

EPS CAGR

10Y-

5Y-

3Y-

TTM38.5%

ROCE

10Y Avg-157.67%

5Y Avg-131.48%

3Y Avg-99.26%

Latest-69.38%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	648.38K	1.91M	2.44M	4.82M	36.14M	3.94M	881.71K	0	0	0
Revenue Growth %	-	1.95%	0.28%	0.98%	6.5%	-0.89%	-0.78%	-1%	-	-
Cost of Goods Sold+	5.89M	15.44M	26.04M	48.61M	89.6M	0	1.64M	1.49M	0	600K
COGS % of Revenue	9.08%	8.08%	10.67%	10.08%	2.48%	-	1.86%	-	-	-
Gross Profit+	-5.24M	-13.53M	-23.6M	-43.79M	-53.46M	3.94M	-757.53K	-1.49M	0	-600K
Gross Margin %	-8.08%	-7.08%	-9.67%	-9.08%	-1.48%	1%	-0.86%	-	-	-
Gross Profit Growth %	-3.17%	-1.58%	-0.74%	-0.86%	-0.22%	1.07%	-1.19%	-0.96%	1%	-
Operating Expenses+	9.5M	21.9M	35M	61.57M	23.64M	126.75M	55.23M	33.35M	45.08M	48.12M
OpEx % of Revenue	14.66%	11.46%	14.34%	12.77%	0.65%	32.19%	62.64%	-	-	-
Selling, General & Admin	3.61M	6.46M	8.96M	12.96M	23.64M	28.48M	20.43M	18.7M	13.91M	16.5M
SG&A % of Revenue	5.57%	3.38%	3.67%	2.69%	0.65%	7.23%	23.17%	-	-	-
Research & Development	5.89M	15.44M	26.04M	48.61M	89.6M	98.27M	36.45M	16.14M	31.17M	32.22M
R&D % of Revenue	9.08%	8.08%	10.67%	10.08%	2.48%	24.96%	41.34%	-	-	-
Other Operating Expenses	0	0	0	0	-89.6M	0	-1.64M	-1.49M	0	-600K
Operating Income+	-8.85M	-19.99M	-32.56M	-56.75M	-77.1M	-122.81M	-55.99M	-34.84M	-45.08M	-48.72M
Operating Margin %	-13.66%	-10.46%	-13.34%	-11.77%	-2.13%	-31.19%	-63.5%	-	-	-
Operating Income Growth %	-2.34%	-1.26%	-0.63%	-0.74%	-0.36%	-0.59%	0.54%	0.38%	-0.29%	-0.08%
EBITDA+	-8.81M	-19.9M	-32.31M	-56.25M	-76.37M	-121.12M	-54.35M	-33.35M	-44.44M	-48.12M
EBITDA Margin %	-13.59%	-10.41%	-13.24%	-11.67%	-2.11%	-30.76%	-61.64%	-	-	-
EBITDA Growth %	-2.34%	-1.26%	-0.62%	-0.74%	-0.36%	-0.59%	0.55%	0.39%	-0.33%	-0.08%
D&A (Non-Cash Add-back)	43.94K	87.66K	255.65K	493.94K	739.38K	1.69M	1.64M	1.49M	641K	600K
EBIT	-8.85M	-19.99M	-32.56M	-56.75M	-77.1M	-122.81M	-55.99M	-40.21M	-40.75M	-38.34M
Net Interest Income+	977	477	183.11K	982.78K	1.23M	-1.03M	-1.83M	-2.13M	-2.92M	4.44M
Interest Income	3.42K	477	183.11K	982.78K	1.23M	0	0	0	0	6.31M
Interest Expense	2.44K	0	0	0	0	1.03M	1.83M	2.13M	2.92M	1.87M
Other Income/Expense	2.95K	-13.62K	141.2K	1.08M	5.65M	11.54M	10.35M	-7.51M	474K	8.51M
Pretax Income+	-8.85M	-20M	-32.42M	-55.67M	-71.45M	-111.27M	-45.64M	-42.35M	-44.6M	-40.21M
Pretax Margin %	-13.65%	-10.46%	-13.29%	-11.54%	-1.98%	-28.26%	-51.76%	-	-	-
Income Tax+	2.44K	13.62K	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.32%	1%	1%
Net Income+	-8.85M	-20M	-32.42M	-55.67M	-71.45M	-111.27M	-45.55M	-55.83M	-44.6M	-40.21M
Net Margin %	-13.65%	-10.46%	-13.29%	-11.54%	-1.98%	-28.26%	-51.66%	-	-	-
Net Income Growth %	-2.48%	-1.26%	-0.62%	-0.72%	-0.28%	-0.56%	0.59%	-0.23%	0.2%	0.1%
Net Income (Continuing)	-8.85M	-20M	-32.42M	-55.67M	-71.45M	-111.27M	-45.64M	-42.35M	-44.6M	-40.21M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-8.47	-14.58	-19.38	-29.30	-32.47	-42.74	-11.11	-10.15	-10.31	-3.68
EPS Growth %	-1.24%	-0.72%	-0.33%	-0.51%	-0.11%	-0.32%	0.74%	0.09%	-0.02%	0.64%
EPS (Basic)	-8.47	-14.58	-19.38	-29.30	-32.47	-42.74	-11.11	-10.15	-10.31	-3.68
Diluted Shares Outstanding	1.05M	1.37M	1.67M	1.9M	2.13M	2.6M	4.1M	4.17M	4.33M	10.91M
Basic Shares Outstanding	1.05M	1.37M	1.67M	1.9M	2.13M	2.6M	4.1M	4.17M	4.33M	10.91M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	12.71M	17.4M	65.5M	44.24M	38.15M	92.07M	100.2M	60.18M	23.55M	152.98M
Cash & Short-Term Investments	12.34M	14.99M	62.54M	41.75M	31.75M	85.43M	97.65M	59.2M	20.91M	149.06M
Cash Only	12.34M	14.99M	62.54M	41.75M	31.75M	85.43M	25.01M	17M	13.72M	17.2M
Short-Term Investments	0	0	0	0	0	0	72.64M	42.19M	7.18M	131.86M
Accounts Receivable	0	1.33M	0	0	2.68M	2.58M	0	0	0	0
Days Sales Outstanding	-	254.05	-	-	27.07	239.02	-	-	-	-
Inventory	0	0	0	0	-2.68M	350K	0	0	0	0
Days Inventory Outstanding	-	0	-	-	-	-	-	-	-	-
Other Current Assets	0	150K	158.99K	2.49M	2.68M	0	192.47K	192.47K	192K	3.91M
Total Non-Current Assets+	160.51K	485.25K	1.47M	2.75M	10.99M	10.22M	7.53M	6.13M	4.73M	2.9M
Property, Plant & Equipment	124.14K	435.25K	1.43M	2.71M	10.9M	9.32M	7M	5.5M	4.04M	2.52M
Fixed Asset Turnover	5.22x	4.39x	1.70x	1.78x	3.32x	0.42x	0.13x	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	36.38K	50K	0	0	0	669.9K	0	0	0	0
Other Non-Current Assets	0	0	40.78K	43.82K	84.97K	234.04K	523.81K	632.77K	690K	385K
Total Assets+	12.88M	17.89M	66.98M	46.99M	49.14M	102.29M	107.73M	66.31M	28.27M	155.88M
Asset Turnover	0.05x	0.11x	0.04x	0.10x	0.74x	0.04x	0.01x	-	-	-
Asset Growth %	0.95%	0.39%	2.74%	-0.3%	0.05%	1.08%	0.05%	-0.38%	-0.57%	4.51%
Total Current Liabilities+	3.63M	8.9M	8.2M	18.09M	34.89M	31.9M	17.01M	12.64M	31.89M	11.82M
Accounts Payable	1.31M	3.42M	3.13M	6.35M	11.09M	7.38M	1.78M	2.17M	3.18M	4.79M
Days Payables Outstanding	81.47	80.86	43.88	47.64	45.18	-	396.85	533.32	-	2.91K
Short-Term Debt	162.02K	271.76K	332.86K	394.31K	752.66K	710.16K	3.86M	3.15M	16.21M	0
Deferred Revenue (Current)	1000K	1000K	0	1000K	0	0	0	0	0	0
Other Current Liabilities	0	788.51K	0	7.63M	3.67M	797K	133.71K	36.87K	39K	2.28M
Current Ratio	3.50x	1.96x	7.98x	2.45x	1.09x	2.89x	5.89x	4.76x	0.74x	12.94x
Quick Ratio	3.50x	1.96x	7.98x	2.45x	1.17x	2.88x	5.89x	4.76x	0.74x	12.94x
Cash Conversion Cycle	-	173.19	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	260.26K	70.36K	989.92K	1.38M	8.1M	25.12M	21.61M	20.68M	3.28M	1.63M
Long-Term Debt	0	0	0	0	0	18.03M	15.64M	15.98M	0	0
Capital Lease Obligations	0	4.63K	0	0	8.1M	7.09M	5.96M	4.68M	3.24M	1.63M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	65.72K	989.92K	1.38M	0	0	22.2K	22.2K	44K	0
Total Liabilities	3.89M	8.97M	9.19M	19.47M	42.98M	57.02M	38.62M	33.32M	35.18M	13.45M
Total Debt+	162.02K	276.39K	332.86K	394.31K	9.45M	26.84M	26.59M	25.09M	20.89M	3.24M
Net Debt	-12.18M	-14.72M	-62.2M	-41.35M	-22.3M	-58.6M	1.58M	8.09M	7.16M	-13.96M
Debt / Equity	0.02x	0.03x	0.01x	0.01x	1.53x	0.59x	0.38x	0.76x	-	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3628.56x	-	-	-	-	-119.42x	-30.59x	-16.34x	-15.42x	-26.03x
Total Equity+	8.99M	8.92M	57.78M	27.52M	6.16M	45.27M	69.11M	32.99M	-6.91M	142.43M
Equity Growth %	0.53%	-0.01%	5.48%	-0.52%	-0.78%	6.35%	0.53%	-0.52%	-1.21%	21.63%
Book Value per Share	8.60	6.50	34.55	14.49	2.89	17.38	16.86	7.91	-1.60	13.05
Total Shareholders' Equity	8.99M	8.92M	57.78M	27.52M	6.16M	45.27M	69.11M	32.99M	-6.91M	142.43M
Common Stock	3.76K	4.47K	5.56K	5.72K	6.47K	9.88K	12.52K	417	0	1K
Retained Earnings	-13.28M	-33.28M	-65.7M	-121.37M	-192.82M	-304.09M	-349.73M	-392.08M	-436.68M	-476.89M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-54.35K	-108.24K	-363.89K	-666.58K	0	0	-62.45K	-126.09K	-1K	35K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.65M	-13.57M	-27.8M	-30.07M	-45.72M	-99.69M	-48.18M	-37.54M	-36.1M	-41.79M
Operating CF Margin %	-7.17%	-7.1%	-11.39%	-6.24%	-1.26%	-25.32%	-54.65%	-	-	-
Operating CF Growth %	-0.97%	-1.92%	-1.05%	-0.08%	-0.52%	-1.18%	0.52%	0.22%	0.04%	-0.16%
Net Income	-8.85M	-20M	-32.42M	-55.67M	-71.45M	-111.27M	-45.64M	-42.35M	-44.6M	-40.21M
Depreciation & Amortization	43.94K	87.66K	255.65K	493.94K	1.23M	1.69M	1.64M	1.49M	641K	-2.74M
Stock-Based Compensation	1.15M	3.16M	5.69M	7.61M	11.98M	0	9.48M	5.72M	0	6.14M
Deferred Taxes	0	14.09K	-8.49K	70.45K	0	0	0	0	0	0
Other Non-Cash Items	-1.98K	75.99K	913.56K	422.34K	45.83K	13.09M	2.03M	1.62M	3.77M	585K
Working Capital Changes	3.01M	3.09M	-2.23M	17.01M	12.48M	-3.2M	-15.7M	-4.02M	4.09M	-5.58M
Change in Receivables	0	-1M	1M	12.5M	2.32M	1.06M	1.62M	0	0	0
Change in Inventory	0	2.11M	-404.24K	5.39M	0	0	0	0	0	0
Change in Payables	972.19K	1.89M	-885.8K	3.9M	4.37M	-3.47M	-5.96M	-256.83K	1.03M	1.6M
Cash from Investing+	-114.04K	-353.03K	-707.43K	-2.3M	-2.74M	-484.49K	-73.42M	30.07M	35.64M	-121.31M
Capital Expenditures	-114.04K	-353.03K	-707.43K	-2.3M	-2.74M	-484.49K	-54.17K	-13.45K	0	0
CapEx % of Revenue	0.18%	0.18%	0.29%	0.48%	0.08%	0.12%	0.06%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	23.9K	0	0	0
Cash from Financing+	10.84M	16.74M	76.01M	11.42M	38.46M	154.87M	60.82M	-533.62K	-2.82M	166.58M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-509.21K	0	-2.94M	-690.18K	-2.57M	0	-1.82M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.76M	-13.92M	-28.5M	-32.37M	-48.46M	-100.17M	-48.24M	-37.56M	-36.1M	-41.79M
FCF Margin %	-7.34%	-7.28%	-11.68%	-6.71%	-1.34%	-25.44%	-54.71%	-	-	-
FCF Growth %	-0.96%	-1.92%	-1.05%	-0.14%	-0.5%	-1.07%	0.52%	0.22%	0.04%	-0.16%
FCF per Share	-4.56	-10.15	-17.04	-17.04	-22.75	-38.46	-11.77	-9.01	-8.34	-3.83
FCF Conversion (FCF/Net Income)	0.53x	0.68x	0.86x	0.54x	0.64x	0.90x	1.06x	0.67x	0.81x	1.04x
Interest Paid	0	0	0	0	29.45K	0	1.74M	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-119.22%	-223.4%	-97.21%	-130.52%	-424.29%	-432.68%	-79.65%	-109.37%	-341.99%	-59.34%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-146.39%	-46.75%	-163.59%	-56.77%
Gross Margin	-808.21%	-707.6%	-967.09%	-908.11%	-147.91%	100%	-85.92%	-	-	-
Net Margin	-1365.05%	-1046.27%	-1328.65%	-1154.48%	-197.69%	-2826.08%	-5166.42%	-	-	-
Debt / Equity	0.02x	0.03x	0.01x	0.01x	1.53x	0.59x	0.38x	0.76x	-	0.02x
Interest Coverage	-3628.56x	-	-	-	-	-119.42x	-30.59x	-16.34x	-15.42x	-26.03x
FCF Conversion	0.53x	0.68x	0.86x	0.54x	0.64x	0.90x	1.06x	0.67x	0.81x	1.04x
Revenue Growth	-	194.8%	27.66%	97.62%	649.51%	-89.11%	-77.61%	-100%	-	-

Frequently Asked Questions

Growth & Financials

Corbus Pharmaceuticals Holdings, Inc. (CRBP) grew revenue by 0.0% over the past year. Growth has been modest.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported a net loss of $67.5M for fiscal year 2024.

Dividend & Returns

Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a return on equity (ROE) of -59.3%. Negative ROE indicates the company is unprofitable.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) had negative free cash flow of $59.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Corbus Pharmaceuticals Holdings, Inc. (CRBP) 10-Year Financial Performance & Capital Metrics

CRBP • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$48M -8.3%
Net Income -$40M +9.9%
EPS (Diluted) -3.68 +64.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -59.34% +82.6%
ROIC -56.77% +65.3%
Debt/Equity 0.02
Interest Coverage -26.03 -68.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-74.45%

EPS CAGR

10Y-

5Y-

3Y-

TTM38.5%

ROCE

10Y Avg-157.67%

5Y Avg-131.48%

3Y Avg-99.26%

Latest-69.38%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	648.38K	1.91M	2.44M	4.82M	36.14M	3.94M	881.71K	0	0	0
Revenue Growth %	-	1.95%	0.28%	0.98%	6.5%	-0.89%	-0.78%	-1%	-	-
Cost of Goods Sold+	5.89M	15.44M	26.04M	48.61M	89.6M	0	1.64M	1.49M	0	600K
COGS % of Revenue	9.08%	8.08%	10.67%	10.08%	2.48%	-	1.86%	-	-	-
Gross Profit+	-5.24M	-13.53M	-23.6M	-43.79M	-53.46M	3.94M	-757.53K	-1.49M	0	-600K
Gross Margin %	-8.08%	-7.08%	-9.67%	-9.08%	-1.48%	1%	-0.86%	-	-	-
Gross Profit Growth %	-3.17%	-1.58%	-0.74%	-0.86%	-0.22%	1.07%	-1.19%	-0.96%	1%	-
Operating Expenses+	9.5M	21.9M	35M	61.57M	23.64M	126.75M	55.23M	33.35M	45.08M	48.12M
OpEx % of Revenue	14.66%	11.46%	14.34%	12.77%	0.65%	32.19%	62.64%	-	-	-
Selling, General & Admin	3.61M	6.46M	8.96M	12.96M	23.64M	28.48M	20.43M	18.7M	13.91M	16.5M
SG&A % of Revenue	5.57%	3.38%	3.67%	2.69%	0.65%	7.23%	23.17%	-	-	-
Research & Development	5.89M	15.44M	26.04M	48.61M	89.6M	98.27M	36.45M	16.14M	31.17M	32.22M
R&D % of Revenue	9.08%	8.08%	10.67%	10.08%	2.48%	24.96%	41.34%	-	-	-
Other Operating Expenses	0	0	0	0	-89.6M	0	-1.64M	-1.49M	0	-600K
Operating Income+	-8.85M	-19.99M	-32.56M	-56.75M	-77.1M	-122.81M	-55.99M	-34.84M	-45.08M	-48.72M
Operating Margin %	-13.66%	-10.46%	-13.34%	-11.77%	-2.13%	-31.19%	-63.5%	-	-	-
Operating Income Growth %	-2.34%	-1.26%	-0.63%	-0.74%	-0.36%	-0.59%	0.54%	0.38%	-0.29%	-0.08%
EBITDA+	-8.81M	-19.9M	-32.31M	-56.25M	-76.37M	-121.12M	-54.35M	-33.35M	-44.44M	-48.12M
EBITDA Margin %	-13.59%	-10.41%	-13.24%	-11.67%	-2.11%	-30.76%	-61.64%	-	-	-
EBITDA Growth %	-2.34%	-1.26%	-0.62%	-0.74%	-0.36%	-0.59%	0.55%	0.39%	-0.33%	-0.08%
D&A (Non-Cash Add-back)	43.94K	87.66K	255.65K	493.94K	739.38K	1.69M	1.64M	1.49M	641K	600K
EBIT	-8.85M	-19.99M	-32.56M	-56.75M	-77.1M	-122.81M	-55.99M	-40.21M	-40.75M	-38.34M
Net Interest Income+	977	477	183.11K	982.78K	1.23M	-1.03M	-1.83M	-2.13M	-2.92M	4.44M
Interest Income	3.42K	477	183.11K	982.78K	1.23M	0	0	0	0	6.31M
Interest Expense	2.44K	0	0	0	0	1.03M	1.83M	2.13M	2.92M	1.87M
Other Income/Expense	2.95K	-13.62K	141.2K	1.08M	5.65M	11.54M	10.35M	-7.51M	474K	8.51M
Pretax Income+	-8.85M	-20M	-32.42M	-55.67M	-71.45M	-111.27M	-45.64M	-42.35M	-44.6M	-40.21M
Pretax Margin %	-13.65%	-10.46%	-13.29%	-11.54%	-1.98%	-28.26%	-51.76%	-	-	-
Income Tax+	2.44K	13.62K	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.32%	1%	1%
Net Income+	-8.85M	-20M	-32.42M	-55.67M	-71.45M	-111.27M	-45.55M	-55.83M	-44.6M	-40.21M
Net Margin %	-13.65%	-10.46%	-13.29%	-11.54%	-1.98%	-28.26%	-51.66%	-	-	-
Net Income Growth %	-2.48%	-1.26%	-0.62%	-0.72%	-0.28%	-0.56%	0.59%	-0.23%	0.2%	0.1%
Net Income (Continuing)	-8.85M	-20M	-32.42M	-55.67M	-71.45M	-111.27M	-45.64M	-42.35M	-44.6M	-40.21M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-8.47	-14.58	-19.38	-29.30	-32.47	-42.74	-11.11	-10.15	-10.31	-3.68
EPS Growth %	-1.24%	-0.72%	-0.33%	-0.51%	-0.11%	-0.32%	0.74%	0.09%	-0.02%	0.64%
EPS (Basic)	-8.47	-14.58	-19.38	-29.30	-32.47	-42.74	-11.11	-10.15	-10.31	-3.68
Diluted Shares Outstanding	1.05M	1.37M	1.67M	1.9M	2.13M	2.6M	4.1M	4.17M	4.33M	10.91M
Basic Shares Outstanding	1.05M	1.37M	1.67M	1.9M	2.13M	2.6M	4.1M	4.17M	4.33M	10.91M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	12.71M	17.4M	65.5M	44.24M	38.15M	92.07M	100.2M	60.18M	23.55M	152.98M
Cash & Short-Term Investments	12.34M	14.99M	62.54M	41.75M	31.75M	85.43M	97.65M	59.2M	20.91M	149.06M
Cash Only	12.34M	14.99M	62.54M	41.75M	31.75M	85.43M	25.01M	17M	13.72M	17.2M
Short-Term Investments	0	0	0	0	0	0	72.64M	42.19M	7.18M	131.86M
Accounts Receivable	0	1.33M	0	0	2.68M	2.58M	0	0	0	0
Days Sales Outstanding	-	254.05	-	-	27.07	239.02	-	-	-	-
Inventory	0	0	0	0	-2.68M	350K	0	0	0	0
Days Inventory Outstanding	-	0	-	-	-	-	-	-	-	-
Other Current Assets	0	150K	158.99K	2.49M	2.68M	0	192.47K	192.47K	192K	3.91M
Total Non-Current Assets+	160.51K	485.25K	1.47M	2.75M	10.99M	10.22M	7.53M	6.13M	4.73M	2.9M
Property, Plant & Equipment	124.14K	435.25K	1.43M	2.71M	10.9M	9.32M	7M	5.5M	4.04M	2.52M
Fixed Asset Turnover	5.22x	4.39x	1.70x	1.78x	3.32x	0.42x	0.13x	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	36.38K	50K	0	0	0	669.9K	0	0	0	0
Other Non-Current Assets	0	0	40.78K	43.82K	84.97K	234.04K	523.81K	632.77K	690K	385K
Total Assets+	12.88M	17.89M	66.98M	46.99M	49.14M	102.29M	107.73M	66.31M	28.27M	155.88M
Asset Turnover	0.05x	0.11x	0.04x	0.10x	0.74x	0.04x	0.01x	-	-	-
Asset Growth %	0.95%	0.39%	2.74%	-0.3%	0.05%	1.08%	0.05%	-0.38%	-0.57%	4.51%
Total Current Liabilities+	3.63M	8.9M	8.2M	18.09M	34.89M	31.9M	17.01M	12.64M	31.89M	11.82M
Accounts Payable	1.31M	3.42M	3.13M	6.35M	11.09M	7.38M	1.78M	2.17M	3.18M	4.79M
Days Payables Outstanding	81.47	80.86	43.88	47.64	45.18	-	396.85	533.32	-	2.91K
Short-Term Debt	162.02K	271.76K	332.86K	394.31K	752.66K	710.16K	3.86M	3.15M	16.21M	0
Deferred Revenue (Current)	1000K	1000K	0	1000K	0	0	0	0	0	0
Other Current Liabilities	0	788.51K	0	7.63M	3.67M	797K	133.71K	36.87K	39K	2.28M
Current Ratio	3.50x	1.96x	7.98x	2.45x	1.09x	2.89x	5.89x	4.76x	0.74x	12.94x
Quick Ratio	3.50x	1.96x	7.98x	2.45x	1.17x	2.88x	5.89x	4.76x	0.74x	12.94x
Cash Conversion Cycle	-	173.19	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	260.26K	70.36K	989.92K	1.38M	8.1M	25.12M	21.61M	20.68M	3.28M	1.63M
Long-Term Debt	0	0	0	0	0	18.03M	15.64M	15.98M	0	0
Capital Lease Obligations	0	4.63K	0	0	8.1M	7.09M	5.96M	4.68M	3.24M	1.63M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	65.72K	989.92K	1.38M	0	0	22.2K	22.2K	44K	0
Total Liabilities	3.89M	8.97M	9.19M	19.47M	42.98M	57.02M	38.62M	33.32M	35.18M	13.45M
Total Debt+	162.02K	276.39K	332.86K	394.31K	9.45M	26.84M	26.59M	25.09M	20.89M	3.24M
Net Debt	-12.18M	-14.72M	-62.2M	-41.35M	-22.3M	-58.6M	1.58M	8.09M	7.16M	-13.96M
Debt / Equity	0.02x	0.03x	0.01x	0.01x	1.53x	0.59x	0.38x	0.76x	-	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3628.56x	-	-	-	-	-119.42x	-30.59x	-16.34x	-15.42x	-26.03x
Total Equity+	8.99M	8.92M	57.78M	27.52M	6.16M	45.27M	69.11M	32.99M	-6.91M	142.43M
Equity Growth %	0.53%	-0.01%	5.48%	-0.52%	-0.78%	6.35%	0.53%	-0.52%	-1.21%	21.63%
Book Value per Share	8.60	6.50	34.55	14.49	2.89	17.38	16.86	7.91	-1.60	13.05
Total Shareholders' Equity	8.99M	8.92M	57.78M	27.52M	6.16M	45.27M	69.11M	32.99M	-6.91M	142.43M
Common Stock	3.76K	4.47K	5.56K	5.72K	6.47K	9.88K	12.52K	417	0	1K
Retained Earnings	-13.28M	-33.28M	-65.7M	-121.37M	-192.82M	-304.09M	-349.73M	-392.08M	-436.68M	-476.89M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-54.35K	-108.24K	-363.89K	-666.58K	0	0	-62.45K	-126.09K	-1K	35K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.65M	-13.57M	-27.8M	-30.07M	-45.72M	-99.69M	-48.18M	-37.54M	-36.1M	-41.79M
Operating CF Margin %	-7.17%	-7.1%	-11.39%	-6.24%	-1.26%	-25.32%	-54.65%	-	-	-
Operating CF Growth %	-0.97%	-1.92%	-1.05%	-0.08%	-0.52%	-1.18%	0.52%	0.22%	0.04%	-0.16%
Net Income	-8.85M	-20M	-32.42M	-55.67M	-71.45M	-111.27M	-45.64M	-42.35M	-44.6M	-40.21M
Depreciation & Amortization	43.94K	87.66K	255.65K	493.94K	1.23M	1.69M	1.64M	1.49M	641K	-2.74M
Stock-Based Compensation	1.15M	3.16M	5.69M	7.61M	11.98M	0	9.48M	5.72M	0	6.14M
Deferred Taxes	0	14.09K	-8.49K	70.45K	0	0	0	0	0	0
Other Non-Cash Items	-1.98K	75.99K	913.56K	422.34K	45.83K	13.09M	2.03M	1.62M	3.77M	585K
Working Capital Changes	3.01M	3.09M	-2.23M	17.01M	12.48M	-3.2M	-15.7M	-4.02M	4.09M	-5.58M
Change in Receivables	0	-1M	1M	12.5M	2.32M	1.06M	1.62M	0	0	0
Change in Inventory	0	2.11M	-404.24K	5.39M	0	0	0	0	0	0
Change in Payables	972.19K	1.89M	-885.8K	3.9M	4.37M	-3.47M	-5.96M	-256.83K	1.03M	1.6M
Cash from Investing+	-114.04K	-353.03K	-707.43K	-2.3M	-2.74M	-484.49K	-73.42M	30.07M	35.64M	-121.31M
Capital Expenditures	-114.04K	-353.03K	-707.43K	-2.3M	-2.74M	-484.49K	-54.17K	-13.45K	0	0
CapEx % of Revenue	0.18%	0.18%	0.29%	0.48%	0.08%	0.12%	0.06%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	23.9K	0	0	0
Cash from Financing+	10.84M	16.74M	76.01M	11.42M	38.46M	154.87M	60.82M	-533.62K	-2.82M	166.58M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-509.21K	0	-2.94M	-690.18K	-2.57M	0	-1.82M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.76M	-13.92M	-28.5M	-32.37M	-48.46M	-100.17M	-48.24M	-37.56M	-36.1M	-41.79M
FCF Margin %	-7.34%	-7.28%	-11.68%	-6.71%	-1.34%	-25.44%	-54.71%	-	-	-
FCF Growth %	-0.96%	-1.92%	-1.05%	-0.14%	-0.5%	-1.07%	0.52%	0.22%	0.04%	-0.16%
FCF per Share	-4.56	-10.15	-17.04	-17.04	-22.75	-38.46	-11.77	-9.01	-8.34	-3.83
FCF Conversion (FCF/Net Income)	0.53x	0.68x	0.86x	0.54x	0.64x	0.90x	1.06x	0.67x	0.81x	1.04x
Interest Paid	0	0	0	0	29.45K	0	1.74M	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-119.22%	-223.4%	-97.21%	-130.52%	-424.29%	-432.68%	-79.65%	-109.37%	-341.99%	-59.34%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-146.39%	-46.75%	-163.59%	-56.77%
Gross Margin	-808.21%	-707.6%	-967.09%	-908.11%	-147.91%	100%	-85.92%	-	-	-
Net Margin	-1365.05%	-1046.27%	-1328.65%	-1154.48%	-197.69%	-2826.08%	-5166.42%	-	-	-
Debt / Equity	0.02x	0.03x	0.01x	0.01x	1.53x	0.59x	0.38x	0.76x	-	0.02x
Interest Coverage	-3628.56x	-	-	-	-	-119.42x	-30.59x	-16.34x	-15.42x	-26.03x
FCF Conversion	0.53x	0.68x	0.86x	0.54x	0.64x	0.90x	1.06x	0.67x	0.81x	1.04x
Revenue Growth	-	194.8%	27.66%	97.62%	649.51%	-89.11%	-77.61%	-100%	-	-

Frequently Asked Questions

Growth & Financials

Corbus Pharmaceuticals Holdings, Inc. (CRBP) grew revenue by 0.0% over the past year. Growth has been modest.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported a net loss of $67.5M for fiscal year 2024.

Dividend & Returns

Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a return on equity (ROE) of -59.3%. Negative ROE indicates the company is unprofitable.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) had negative free cash flow of $59.5M in fiscal year 2024, likely due to heavy capital investments.